Utrecht-based Cleara, a company on a mission to target cellular senescence to extend human healthspan and to counteract late-stage cancer, announced on Tuesday, September 27, that it raised $2.5M (approximately €2.58M) in a Seed round of funding earlier in the year.
The investment was led by Apollo Health Ventures, with participation from Curie Capital, ROM Utrecht Region, and Longevity Tech Fund.
Cleara says it will use the funds to progress its compounds toward clinical development and further build the company’s developmental pipeline and management team.
What does Cleara offer?
Founded in 2018, Cleara is a preclinical-stage biotechnology company focused on developing therapies for treating different pathologies of “scarred cellular” senescence, including late-stage cancer and chronic diseases.